CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Up 33.3% in March

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN - Get Free Report) was the recipient of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 10,800 shares, a growth of 33.3% from the March 15th total of 8,100 shares. Based on an average trading volume of 8,200 shares, the short-interest ratio is currently 1.3 days. Approximately 0.1% of the company's shares are sold short.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a "buy" rating and set a $11.00 price target on shares of CollPlant Biotechnologies in a research note on Friday, April 5th.

Hedge Funds Weigh In On CollPlant Biotechnologies

Several large investors have recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. raised its stake in shares of CollPlant Biotechnologies by 11.3% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 50,150 shares of the company's stock valued at $320,000 after acquiring an additional 5,100 shares during the last quarter. Villere ST Denis J & Co. LLC raised its stake in CollPlant Biotechnologies by 20.4% during the fourth quarter. Villere ST Denis J & Co. LLC now owns 361,293 shares of the company's stock worth $2,309,000 after buying an additional 61,120 shares during the last quarter. Bank of America Corp DE raised its stake in CollPlant Biotechnologies by 53.9% during the first quarter. Bank of America Corp DE now owns 7,389 shares of the company's stock worth $52,000 after buying an additional 2,589 shares during the last quarter. Credit Suisse AG bought a new position in CollPlant Biotechnologies during the fourth quarter worth $51,000. Finally, Jane Street Group LLC bought a new position in CollPlant Biotechnologies during the third quarter worth $90,000. Institutional investors own 21.69% of the company's stock.

CollPlant Biotechnologies Stock Up 0.4 %

Shares of CLGN stock traded up $0.02 during trading hours on Friday, hitting $5.25. 1,782 shares of the company's stock traded hands, compared to its average volume of 5,155. The stock's 50 day simple moving average is $5.30 and its 200 day simple moving average is $5.44. The stock has a market cap of $60.06 million, a PE ratio of -8.20 and a beta of 0.24. CollPlant Biotechnologies has a 12 month low of $4.22 and a 12 month high of $8.90.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.